Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
With the ongoing shortage of GLP1 drugs, we are dedicated to supporting patients with our innovative compounded solution
Analysts say the worldwide market for obesity and diabetes drugs based on GLP1s could exceed $100 billion to $150 billion annually later this decade, with access remaining patchy outside the US and parts of Europe
Multiple medications now exist, each with slightly different properties
For patients, these cost saving measures can feel frustrating and counterproductive
The maximum recommended daily dose is 100 mg of sitagliptin and 2000 mg of metformin hydrochloride (HCl) extended-release
Effects on vulnerable populations (pregnant women, children, immunocompromised individuals) are unknown
US$ 20.96
US$ 25.72
US$ 27.52
US$ 23.98
US$ 20.95
US$ 28.24
US$ 22.43
US$ 26.14
US$ 28.19
US$ 23.91
US$ 28.16
US$ 22.71
US$ 22.42
US$ 25.45
